#45 Clinical Context
Background information relevant to the evolving cannabis medicine landscape.
Clinicians in Nebraska need to understand that their state’s continued absence from federal protections for state-level medical cannabis laws creates legal and prescribing uncertainty that could affect patient access to cannabis-based treatments. Without explicit federal protection like other states have secured, Nebraska providers face greater liability risks when recommending or discussing cannabis options with patients who might benefit from it. This legislative gap directly impacts clinical decision-making and the ability to provide comprehensive, evidence-based treatment discussions with patients seeking cannabis as a therapeutic option.
Senator Pete Ricketts declined to commit to supporting Nebraska’s inclusion in the Strengthening the Tenth Amendment Through Entrusting States (STATES) Act, which would protect state-authorized medical cannabis programs from federal DEA enforcement. This legislative gap leaves Nebraska patients and providers vulnerable to potential federal prosecution despite any state-level authorization, creating legal uncertainty that discourages both patient access and clinician participation in cannabis medicine. The lack of federal protection affects how physicians can counsel patients about medical cannabis without risking their own legal standing, and it may prevent development of standardized clinical protocols for cannabis-based treatments in states without explicit federal safe harbor. For clinicians and patients in Nebraska and similar states lacking this protection, the absence of federal legislative support creates a persistent barrier to establishing legitimate medical cannabis programs, even where there is local support for such initiatives.
“The reality is that patients in Nebraska with legitimate medical needs are being denied access to a treatment option that’s legal in 38 states, and their physicians like me can’t even discuss it as a clinical option without legal jeopardy, which puts us in an untenable position ethically.”
🏛️ Nebraska’s exclusion from the Strengthening the Tenth Amendment Through Entrusting States (STATES) Act represents an ongoing policy gap that may affect patients in that state who could otherwise benefit from medical cannabis under state law, despite federal prohibition. While the article does not detail the specific reasons for Nebraska’s omission, healthcare providers should recognize that such legislative inconsistencies create practical uncertainty for clinicians in states without explicit federal carve-outs, particularly regarding liability exposure, insurance coverage, and documentation standards. The lack of federal-state alignment on medical cannabis also complicates patient counseling, since providers cannot reliably discuss therapeutic options that may be legal under state statutes but remain federally prohibited. Clinicians should stay informed about evolving state and federal policy in their jurisdictions and consider documenting patient discussions about all treatment options, including cannabis where state law permits, while remaining transparent about the uncertain legal and safety landscape. Understanding these policy
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: